Mild Diabetic Retinopathy: Early Detection and Care
Understanding Mild Nonproliferative Diabetic Retinopathy
Diabetic retinopathy is a complication of diabetes that damages the small blood vessels in the retina. Over time, high blood sugar weakens the walls of these tiny vessels. This damage can cause the vessels to leak fluid or blood, and in later stages, abnormal new blood vessels can grow on the surface of the retina. Diabetic retinopathy is the leading cause of vision loss among working-age adults.
An estimated many millions people in the United States had diabetic retinopathy in 2021, representing about a substantial proportion of all people with diabetes (PMC, National Institutes of Health, 2023). Diabetic retinopathy progresses through stages, from mild to moderate to severe nonproliferative disease, and eventually to proliferative diabetic retinopathy if left unmanaged.
Nonproliferative diabetic retinopathy (NPDR) is classified into mild, moderate, and severe stages. In mild NPDR, the only visible finding is the presence of microaneurysms. Microaneurysms are tiny, outward balloonings of the capillary walls in the retina. They are the earliest detectable sign that diabetes is affecting the eye's blood vessels.
At this stage, there is no abnormal new blood vessel growth, which is why it is called 'nonproliferative.' The retina may look nearly normal to the patient, and vision is typically unaffected. However, a retina specialist can detect microaneurysms during a dilated eye exam or with advanced imaging.
Chronic high blood sugar causes damage to the cells that support the tiny blood vessels in the retina. Specifically, cells called pericytes begin to die off, and the basement membrane of the capillaries thickens. These structural changes weaken the vessel walls. Small bulges, or microaneurysms, form at the weakened points. They are usually found first on the temporal side (toward the ear) of the macula, the central part of the retina responsible for sharp vision.
Microaneurysms may occasionally rupture, causing tiny dot-shaped hemorrhages (bleeding spots) within the retina. In mild NPDR, these hemorrhages are minimal. If the disease progresses, more widespread bleeding, fluid leakage, and other vascular abnormalities develop.
Who Is Affected and Risk Factors
The length of time a person has lived with diabetes is one of the strongest risk factors for developing diabetic retinopathy. The longer someone has diabetes, the more likely the retinal blood vessels are to show damage. Data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy showed that after 20 years of diabetes, 99% of patients with type 1 diabetes and 60% of patients with type 2 diabetes showed some degree of retinopathy (WESDR).
Poorly managed blood sugar levels significantly increase the risk of developing and worsening diabetic retinopathy. Elevated hemoglobin A1c (HbA1c), a measure of average blood sugar over approximately three months, is closely linked to higher rates of retinal damage. Maintaining blood sugar within a target range recommended by a primary care doctor or endocrinologist is one of the most important steps for protecting eye health.
High blood pressure places additional stress on the already fragile blood vessels of the retina. When combined with high blood sugar, elevated blood pressure accelerates damage. High cholesterol can also contribute to the progression of diabetic retinopathy by promoting deposits and vascular changes in the retina. Managing both blood pressure and cholesterol through medication and lifestyle changes helps reduce eye-related risks.
Several additional factors can increase the likelihood of developing diabetic retinopathy or experiencing progression from mild to more advanced stages. These include:
- Tobacco use, which damages blood vessels throughout the body including the retina
- Being Black, Latino, or Native American, as these populations have higher rates of both diabetes and diabetic retinopathy
- Pregnancy, which can temporarily worsen existing diabetic retinopathy
- Kidney disease related to diabetes, which often accompanies retinal vascular damage
Signs and Symptoms
Most people with mild nonproliferative diabetic retinopathy notice no changes in their vision. The microaneurysms that define this stage are microscopic and located in the retinal blood vessels, not in the visual pathway itself. Because there is typically no fluid leakage into the central macula at this stage, visual acuity remains normal.
This is precisely why regular dilated eye exams are so important for people with diabetes. Waiting for symptoms to appear before seeking an exam means the disease may have already advanced to a more serious stage.
As diabetic retinopathy progresses beyond the mild stage, symptoms can begin to appear. These may include:
- Spots or dark strings floating in the field of vision, called floaters
- Blurred or fluctuating vision
- Dark or empty areas in the visual field
- Difficulty seeing colors clearly
- Vision loss that may come on gradually or suddenly
Some symptoms signal a possible emergency and require urgent evaluation. Anyone with diabetes who experiences a sudden increase in floaters, flashes of light, a curtain or shadow across part of the vision, or sudden vision loss in one eye should see a retina specialist or go to the emergency room immediately. These symptoms may indicate progression to a sight-threatening complication such as vitreous hemorrhage (bleeding into the gel of the eye) or retinal detachment.
Diagnosis and Testing
A dilated eye exam is the standard method for detecting diabetic retinopathy. During this exam, drops are placed in the eyes to widen the pupils. A retina specialist then uses a special lens and light to examine the retina directly. In mild NPDR, the specialist looks for the characteristic microaneurysms, which appear as tiny red dots on the retina. This exam can detect diabetic retinopathy before any symptoms arise.
Optical coherence tomography (OCT) is a noninvasive imaging test that creates detailed cross-sectional pictures of the retina. It allows a retina specialist to measure retinal thickness and detect any early fluid accumulation or swelling. In mild NPDR, OCT is often normal, but it serves as an important baseline for tracking any changes over time. If diabetic macular edema (swelling of the central retina) develops later, OCT is the primary tool for monitoring it.
Fluorescein angiography is a diagnostic test in which a special dye is injected into a vein in the arm. As the dye circulates through the retinal blood vessels, a camera takes rapid photographs. This test highlights microaneurysms, areas of leakage, and regions where blood flow is reduced. Fluorescein angiography is not routinely needed for mild NPDR but may be used if a retina specialist suspects the disease is more advanced than it appears on clinical exam.
Fundus photography (photographs of the back of the eye) is often used to document the appearance of the retina at each visit. Some screening programs now use artificial intelligence to analyze retinal photographs for signs of diabetic retinopathy. These tools can help identify patients who need a referral to a retina specialist. However, a comprehensive dilated exam remains the gold standard for diagnosis and staging.
Treatment Options
For mild NPDR, the most important treatment is controlling blood sugar levels. Strict glycemic control has been shown to slow the progression of diabetic retinopathy and reduce the risk of vision-threatening complications. Working closely with a primary care doctor or endocrinologist to maintain HbA1c within a target range is the foundation of care at this stage.
It is worth noting that rapid, dramatic reductions in blood sugar can sometimes temporarily worsen diabetic retinopathy. This has been observed with some newer diabetes medications, including certain GLP-1 receptor agonists. A retina specialist and the diabetes care team should coordinate treatment when major changes in blood sugar management are planned.
Managing high blood pressure and high cholesterol is an essential part of slowing diabetic retinopathy progression. Medications prescribed by a primary care doctor, along with dietary changes, regular exercise, and smoking cessation, all contribute to reducing stress on the retinal blood vessels. These systemic health measures complement eye-specific monitoring and treatment.
In mild NPDR, active eye treatments such as laser therapy or injections are not typically necessary. The focus at this stage is observation and systemic management. Patients with mild NPDR can generally be monitored with dilated eye exams every 6 to 12 months, depending on the stability of their findings and overall diabetes control. Only 5% to 10% of patients with minimal or mild diabetic retinopathy progress to more advanced stages within one year (American Academy of Ophthalmology).
Anti-VEGF (vascular endothelial growth factor) injections are medications that block abnormal blood vessel growth and reduce fluid leakage in the retina. While anti-VEGF therapy is not indicated for mild NPDR alone, it becomes a treatment option if the disease progresses or if diabetic macular edema develops. Common anti-VEGF medications used in diabetic eye disease include Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab), which is used off-label for eye conditions as it is FDA-approved only for cancer treatment.
Vabysmo (faricimab) is a newer bispecific antibody approved for diabetic macular edema that targets both VEGF and angiopoietin-2. The PANORAMA study demonstrated that intravitreal aflibercept reduced the risk of vision-threatening complications by 77% to 83% compared with no treatment at 100 weeks in patients with moderately severe to severe NPDR (PANORAMA, Regeneron). These results underscore the importance of monitoring mild NPDR so that treatment can begin promptly if the disease advances.
What to Expect
Most people with mild NPDR maintain stable vision for many years, especially with good diabetes control. However, progression is possible. Approximately 16% of cases of mild NPDR progress to proliferative stages within four years (StatPearls, National Library of Medicine). The cumulative occurrence of progression from mild NPDR to vision-threatening complications has been estimated at 14% to 16% over time (Nature Eye, 2025).
These numbers highlight the importance of regular follow-up. Even though mild NPDR does not usually threaten vision on its own, it requires ongoing attention to prevent more serious disease from developing undetected.
At each follow-up visit, a retina specialist will perform a dilated eye exam to check for any new microaneurysms, hemorrhages, or signs of fluid leakage. OCT imaging may be repeated to track retinal thickness. The specialist will also review blood sugar levels, blood pressure readings, and any changes in diabetes medications. The typical follow-up interval for mild NPDR is every 6 to 12 months, but this may be adjusted based on individual risk factors.
With good systemic control, mild NPDR can remain stable for years or even improve in some cases. Some microaneurysms may resolve on their own. However, if blood sugar, blood pressure, or cholesterol remain poorly controlled, the disease is more likely to progress through the stages of NPDR and potentially to proliferative diabetic retinopathy, where abnormal new blood vessels grow and can cause serious vision loss. Early detection at the mild stage provides the best opportunity to take action and preserve vision.
Living With Mild Nonproliferative Diabetic Retinopathy
Living with mild NPDR means making diabetes management a daily priority. Checking blood sugar regularly, taking medications as prescribed, eating a balanced diet, and staying physically active all contribute to slowing the progression of retinal damage. Even small, consistent improvements in blood sugar control can make a meaningful difference in long-term eye health.
Managing diabetic retinopathy involves coordination between multiple health care providers. A primary care doctor or endocrinologist manages blood sugar, blood pressure, and cholesterol. A retina specialist monitors the eyes and determines when imaging or treatment is needed. Keeping all members of the care team informed about changes in health, medications, or symptoms helps ensure comprehensive and timely care.
Receiving a diagnosis of diabetic retinopathy, even at the mild stage, can be concerning. It is natural to worry about the possibility of vision loss. Understanding that mild NPDR is a manageable condition, especially with proactive care, can help ease some of that concern. Support groups, diabetes education programs, and patient advocacy organizations such as the BrightFocus Foundation and the American Diabetes Association offer resources for people living with diabetic eye disease.
When to See a Retina Specialist
The American Academy of Ophthalmology recommends that people with type 1 diabetes have a comprehensive dilated eye exam within five years of diagnosis. People with type 2 diabetes should have an exam at the time of diagnosis, since the disease may have been present for years before it was detected. After an initial exam, people with diabetes should have a dilated eye exam at least once a year, or more frequently if any retinopathy is found.
Between scheduled exams, certain changes should prompt a visit to a retina specialist sooner rather than later. These include:
- New or increased floaters
- Blurred vision that does not improve
- Difficulty reading or seeing faces clearly
- Any sudden change in vision
A sudden increase in floaters, flashes of light, or a shadow over part of the vision requires immediate evaluation. These symptoms may indicate a serious complication such as vitreous hemorrhage or retinal detachment. See a retina specialist or go to the emergency room immediately if any of these occur.
Questions and Answers
In some cases, microaneurysms associated with mild NPDR can improve or resolve with better blood sugar control. However, the underlying susceptibility to retinal vascular damage remains as long as a person has diabetes. The goal of management is to prevent progression rather than to achieve a complete cure. Sustained improvements in HbA1c, blood pressure, and cholesterol offer the best chance of stabilizing or improving mild NPDR.
No. Mild NPDR is the earliest and least severe stage of diabetic retinopathy. The vast majority of people with mild NPDR do not experience significant vision loss, especially when blood sugar and blood pressure are well managed. Approximately a notable percentage of mild NPDR cases progress to proliferative stages over four years (StatPearls, National Library of Medicine), and those cases can often be treated effectively if caught early. Regular eye exams and proactive diabetes care are the strongest safeguards against vision loss.
Eye injections are not typically needed for mild NPDR. Treatment at this stage focuses on controlling blood sugar, blood pressure, and cholesterol, along with regular monitoring by a retina specialist. Anti-VEGF injections such as Eylea (aflibercept) or Lucentis (ranibizumab) become relevant only if the disease progresses to more advanced stages or if diabetic macular edema develops. A retina specialist will recommend injections only when there is a clear clinical need.
For mild NPDR, most retina specialists recommend follow-up exams every 6 to 12 months. The exact interval depends on factors such as blood sugar control, blood pressure, the presence of other diabetes complications, and whether any changes were noted at the last visit. People with well-controlled diabetes and stable findings may be seen annually, while those with additional risk factors may benefit from more frequent monitoring.
Yes. Research consistently shows that controlling blood sugar, blood pressure, and cholesterol slows the progression of diabetic retinopathy. Even modest improvements in HbA1c can reduce the risk of the disease advancing to sight-threatening stages. Regular physical activity, a balanced diet rich in vegetables and whole grains, not smoking, and taking prescribed medications all contribute to better outcomes. These changes protect not only the eyes but also the heart, kidneys, and nerves from diabetes-related damage.